Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q2 | Aug 14, 2025 | RTW Investments | - | 1.4% | AKRO, GHRS, RNA, TARS, URGN | Biotechnology, China, FDA, Gene Therapy, GLP-1, M&A, Obesity, Rare Disease | Significant M&A activity continued with Merck's $10 billion acquisition of Verona Pharma, Sanofi's $1.2 billion acquisition of Vicebio, and Novartis's $1 billion acquisition of Matchpoint. Avidity Biosciences is reportedly evaluating a potential acquisition offer from Novartis. | View | |
| 2025 Q1 | Mar 31, 2025 | RTW Investments | -6.4% | -6.4% | AKRO, IMCR, RCKT, RNA, TARS | Biopharma M&A, Biotechnology, Clinical Trials, Gene Therapy, Life Sciences, Oncology, Rare Diseases, small cap | RTW Bio focuses on identifying transformative assets across the life sciences sector with deep scientific and commercial expertise. The portfolio includes 56 core positions across therapeutics and medtech, with exposure spanning small molecules, genetic medicines, proteins, and antibodies. Development stage companies are concentrated in Phase 3 trials representing 53% of exposure. | View | |
| 2024 Q4 | Dec 31, 2024 | RTW Investments | -7.3% | -4.6% | AKRO, IMCR, RCKT, RNA, TARS | Biotechnology, FDA, Gene Therapy, GLP1, innovation, M&A, Rare Diseases | The fund focuses on identifying transformative assets across the life sciences sector with deep scientific and commercial expertise. Medical science innovation has never been better, and the FDA appears willing to support it with 56 novel drugs approved this year. The sector is experiencing attractive valuations and improving financing and M&A activities. | View | |
| 2025 Q3 | Oct 14, 2025 | RTW Investments | - | 17.5% | AKRO, PTCT, QURE, RNA, STOK, TARS, URGN, VSTM | Biotechnology, Commercial, Development, Gene Therapy, M&A, Oncology, Rare Diseases | Development stage M&A activity accelerated in September with three significant acquisitions announced over two weeks. Roche acquired MASH company 89Bio for $2.4 billion, Pfizer bought Metsera's obesity pipeline for $4.9 billion, and Genmab acquired Merus for $8 billion. Multinational pharmas have worked through manufacturing and tariff uncertainties and have more clarity on their budgets, leading to expectations of more development stage deals. | View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| No pitches found. | |||||||||
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||